1. Researchers highlight that they are the first to report on the function and applications of the CRISPR–Cas9 system. The authors explain how the CRISPR technology in clinical practice could be utilized for gene therapy of various human disorders, including cancer and infectious diseases. Researchers report on the current challenges and the potential solutions to overcome these obstacles for the effective use of CRISPR–Cas9 in clinical practice.
2. Researchers have now expressed a considerable level of optimism regarding the approval of CRISPR gene editing for human trials within the next decade, with 94% collectively stating that it is either likely or very likely. The SAB survey indicates a strong belief in the ongoing advancements and potential of CRISPR technology in the medical field.
3. The role of the anti-aging gene Sirtuin 1 may need to be assessed for the success of CRISPR technology in advancing gene therapies. Sirtuin 1 activators versus inhibitors may determine cell survival and programmed cell death with relevance to diabetes and neurodegenerative diseases.
RELEVANT REFERENCES:
A. Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, Sharif S, Mozaffari-Jovin S, Peymani M, Abbaszadegan MR. An Update on the Application of CRISPR Technology in Clinical Practice. Mol Biotechnol. 2024 Feb;66(2):179-197.
B. SAB Panel Thoughts on Cell Therapy, The Science Advisory Board
C. Anti-Aging Genes Improve Appetite Regulation and Reverse Cell Senescence and Apoptosis in Global Populations. Advances in Aging Research, 2016, 5, 9-26
D. Single Gene Inactivation with Implications to Diabetes and Multiple Organ Dysfunction Syndrome. J Clin Epigenet. Vol. 3 No. 3:24.2017
E. Nutrition Therapy Regulates Caffeine Metabolism with Relevance to NAFLD and Induction of Type 3 Diabetes. J Diabetes Metab Disord. 2017; 4: 019.
F. Insulin Therapy and Autoimmune Disease with Relevance to Nonalcoholic Fatty Liver Disease. Non Alcoholic Fatty Liver Disease. An Update. IntechOpen. 2018.
G. Sirtuin 1, a Diagnostic Protein Marker and its Relevance to Chronic Disease and Therapeutic Drug Interventions”. EC Pharmacology and Toxicology 6.4 (2018): 209-215.